ArticleClinical rheumatology2026
Associations of cardiovascular health and genetic susceptibility with incident psoriatic arthritis: findings from two cohort studies.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionPsoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, may be influenced by cardiovascular health (CVH). This study aims to investigate the associations between three CVH scores (Life's Simple 7 (LS7), Life's Essential 8 (LE8), and Life's Crucial 9 (LC9)) and a psychological health (PH) score with PsA risk and potential interactions with genetic susceptibility.
methodsUsing data from the UK Biobank and NHANES cohorts, we conducted prospective and cross-sectional analyses employing Cox proportional hazards and multivariable logistic regression models, respectively. Additionally, a polygenic risk score (PRS) was derived in the UK Biobank to quantify genetic susceptibility to PsA and examine its interactions with CVH and PH metrics.
resultsHigher scores in LE8, LC9, and PH showed consistent inverse associations with PsA, with the most pronounced association observed for LC9. Higher LC9 scores showed a strong inverse association with PsA (highest vs lowest group: OR = 0.25 (95% CI 0.05, 0.86), HR = 0.20 (95% CI 0.06, 0.65)). Each 10-point LC9 increase corresponded to lower PsA risk (OR = 0.76 (95% CI 0.58, 0.98), HR = 0.68 (95% CI 0.54, 0.86)). Genetic risk (assessed as the inverse of the PRS) showed significant antagonistic interactions with LE8, LC9, and PH scores.
conclusionInverse associations were observed between LE8, LC9, and PH scores and PsA risk, along with notable interactions with genetic predisposition. Key Points • Higher LE8, LC9, and PH scores showed inverse associations with PsA. • LC9 showed the strongest inverse association with PsA in both cohorts. • Genetic susceptibility showed antagonistic interactions with LE8, LC9 and PH scores.
Indexed as
Identifiers
42286265What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.